Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

Phase 1 Completed 40 enrolled HanAll BioPharma Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of HL-032 after oral administration in healthy male volunteers.

Timeline

Start: 2011-09
Primary completion: 2011-12
Completion: 2012-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Somatropin	Protein / enzyme biologic	5 mg	Subcutaneous

Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers

Summary

Timeline

Drugs

Indications